Activity of host antimicrobials against multidrug resistant. Acinetobacter baumannii acquiring colistin resistance through loss of. lipopolysaccharide
|
|
- Shanna Agnes Hicks
- 5 years ago
- Views:
Transcription
1 AAC Accepts, published online ahead of print on 24 February 2014 Antimicrob. Agents Chemother. doi: /aac Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 SHORT FORM PAPER Activity of host antimicrobials against multidrug resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide Meritxell García-Quintanilla, Marina R. Pulido, Patricia Moreno-Martínez, Reyes Martín-Peña, Rafael López-Rojas, Jerónimo Pachón and Michael McConnell Biomedical Institute of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/ University of Sevilla, 41013, Sevilla, Spain. Author to whom correspondence should be addressed: Michael J. McConnell Biomedical Institute of Seville Hospital Universitario Virgen del Rocío Avenida Manuel Siurot s/n, Sevilla, Spain mcconnell.mike75@gmail.com Phone: Running Title: LPS deficient A. baumannii and host antimicrobials 23 Key Words: host cationic peptides, antibiotic resistance, human lysozyme, LL-37
2 Abstract Acinetobacter baumannii can acquire resistance to the cationic peptide antibiotic colistin through complete loss of lipopolysaccharide expression. The activity of the host cationic antimicrobials LL-37 and human lysozyme against multidrug resistant clinical isolates of A. baumannii that acquired colistin resistance through lipopolysaccharide loss was characterized. We demonstrate that LL-37 has similar activity against strains lacking lipopolysaccharide compared to their colistin sensitive parent strains, whereas human lysozyme has increased activity against colistin resistant strains lacking LPS. Downloaded from on August 31, 2018 by guest 2
3 Colistin is a cationic peptide antibiotic and one of the few antimicrobials that retains activity against many isolates of multidrug resistant Acinetobacter baumannii. Unfortunately, colistin resistant clinical isolates of A. baumannii have been reported (1-3). Two mechanisms for acquiring colistin resistance have been described in A. baumannii, ethanolamine addition to the lipid A moiety of lipopolysaccharide (LPS) resulting from mutations in the PmrAB two-component system (4, 5), and complete loss of LPS expression due to mutation in the lpxa, lpxc and lpxd genes, which encode the enzymes that catalyze the first steps in LPS biosynthesis (6, 7). Both mechanisms are thought to reduce the activity of colistin by decreasing the electrostatic interactions between positively charged colistin molecules and the bacterial membrane due to negatively charged LPS. Host cationic antimicrobials play an important role in the innate immune response to infections caused by Gram-negative bacteria. LL-37 is an antimicrobial peptide primarily expressed by epithelial cells and neutrophils (8), and has been shown to have antibacterial activity against various pathogens, including A. baumannii (9, 10). Human lysozyme is present in mucosal secretions, and produces membrane damage in bacteria by hydrolyzing components of the peptidoglycan layer (11). The cationic C- terminal domain has been shown to have antibacterial activity produced via membrane permeabilization (12, 13). Importantly, a recent study has demonstrated that A. baumannii clinical isolates that acquired colistin resistance through mutations in the PmrAB system developed cross-resistance to LL-37 and human lysozyme, suggesting that a potential risk associated with the use of colistin could be the selection of strains that have reduced susceptibility to effectors of the host innate immune system (10). In this context, and given that LPS is thought to play an important role in mediating the activity of cationic antimicrobials due to its negative charge, the objective of the present 3
4 study was to assess the activity of LL-37 and human lysozyme on multidrug resistant clinical isolates of A. baumannii that acquired colistin resistance through complete loss of LPS. Isolation of LPS deficient strains. Colistin resistance was selected for in four previously characterized, clonally distinct multidrug resistant clinical isolates of A. baumannii (14) by plating overnight cultures of each strain on Mueller-Hinton agar containing 10 mg/l of colistin, as described previously (7). In all cases, colistin resistant colonies appeared after incubation for 24 hours at 37 ºC. Sequencing of the lpxa, lpxc and lpxd genes of these isolates identified derivatives that harbored mutations in these genes that produced either amino acid changes or a premature stop codon (Table 1). Derivatives were confirmed as colistin resistant by determining colistin MICs by broth microdilution according to Clinical Laboratory Standards Institute guidelines (15), and all strains showed high level resistance to colistin (Table 1). The loss of LPS was confirmed by using the QCL-1000 Limulus Amebocyte Assay (Lonza) according to the manufacturer s instructions to quantify endotoxin levels in three independent cultures of each strain (Table 1). Two previously described strains that acquired colistin resistance due to mutations in the PmrAB system, RC64 (16, 17) and CR17 (1), and their colistin susceptible parental counterparts were included for comparison (Table 1). Antimicrobial activity of LL-37 on LPS deficient strains. The activity of LL- 37 against each strain included in the study was determined based on a previously described assay (10). Bacterial cells were resuspended in 10 mm sodium phosphate buffer (ph 6.5) and adjusted to an OD 600 of 0.5. The bacterial suspensions were diluted 1:100 and 100 µl were mixed with 100 µl 10 mm sodium phosphate buffer containing the indicated concentrations of LL-37 (Sigma) and incubated for 3 hours at 37ºC. After incubation, cell viability was measured by plating serial dilutions on blood agar. 4
5 Differences in bacterial survival between groups were determined using the Student s t test, and a P value 0.05 was considered significant. The antimicrobial activity of LL- 37 on the clinical isolates and their colistin resistant mutants was characterized using concentrations ranging from 0 to 3.13 µg/ml on the basis that these concentrations are similar to concentrations of LL-37 encountered in human plasma and in mucosal secretions (18, 19). As can be seen in Figure 1A, LL-37 demonstrated antimicrobial activity against all four of the parental clinical isolates in the dose range tested, with survival between 0.1% and 0.01% at a concentration of 3.13 µg/ml. In general, the antimicrobial activity of LL-37 against the LPS deficient derivatives of the clinical isolates showed a similar pattern of susceptibility, indicating that a lack of LPS had little effect on the activity of LL-37 on A. baumannii. It is interesting to note, however, that the 167R strain appeared to show approximately 100-fold less susceptibility to LL-37 at a concentration of 1.56 µg/ml. Characterization of the A. baumannii strains that had acquired colistin resistance due to mutations in the PmrAB system (RC64 and CR17; Figure 1A) demonstrated that had similar antimicrobial activity against these strains and their colistin-susceptible parent strains. Antimicrobial activity of human lysozyme on LPS deficient strains. The susceptibility assay for human lysozyme (Sigma) was performed similarly as for LL-37 except that a one hour incubation time was employed. The antimicrobial activity of human lysozyme at concentrations of 0 to 1.56 mg/ml was assessed on the basis that these concentrations are similar to those encountered in the upper respiratory tract (20). Interestingly, in contrast to the results obtained with LL-37, LPS deficient derivatives showed dramatically increased susceptibility to human lysozyme compared to their parental counterparts (Figure 1B). Even at the low concentrations of lysozyme tested (0.05 to 0.1 mg/ml) differences of between 100- and 10,000-fold were seen between the 5
6 derivatives and the parental strains. These results indicate that LPS loss increases the susceptibility of A. baumannii to human lysozyme at physiological concentrations. Characterization of strains acquiring resistance to colistin via mutations in the PmrAB system demonstrated that the RC64 strain was more sensitive to lysozyme than its corresponding parental strain at the concentrations tested, whereas CR17 showed modestly increased resistance to lysozyme at the lower concentrations tested (Figure 1B). These results may indicate that the effect of LPS modification on lysozyme susceptibility is, at least in part, strain specific. Resistance to colistin in A. baumannii via LPS modification or complete loss of LPS expression is thought to result from decreased electrostatic attraction between positively charged colistin molecules and the bacterial membrane due to negatively charged LPS. This raises the possibility that other cationic antimicrobial agents, such as LL-37 and human lysozyme, may have decreased activity against A. baumannii strains that acquire resistance to colistin. Data supporting this idea were recently reported in which A. baumannii clinical isolates with mutations in the pmrb gene, and thus presumably ethanolamine modifications of LPS, showed decreased susceptibility to LL- 37 and human lysozyme compared to their colistin susceptible parent strains (10). These results are in contrast to the results presented here in that the present study provides evidence that complete loss of LPS expression during the acquisition of colistin resistance in A. baumannii minimally affects the antimicrobial activity of LL- 37, and increases susceptibility to human lysozyme. The fact that the antimicrobial activity of LL-37 was minimally affected by LPS loss is in some ways surprising given that, like colistin, LL-37 is a cationic antimicrobial peptide and it has been proposed that the initial target of LL-37 in Gram-negative bacteria is LPS (21). This finding may suggest that the mechanism used by LL-37 to achieve antimicrobial activity is, at least 6
7 in part, different from that used by colistin. This idea is supported by reports describing the antimicrobial activity of LL-37 on Gram-positive bacteria and fungi, which lack LPS (22). Interestingly, a recent study showed that an LPS deficient derivative of the ATCC strain of A. baumannii was modestly more sensitive to LL-37 than the parent strain, suggesting that the effect of LPS loss on LL-37 activity may be strain specific (9), although it is important to note that the four strains used in the present study are clonally distinct. The data presented here demonstrate that LPS loss in A. baumannii results in increased susceptibility to human lysozyme. One possible explanation is that the loss of LPS in the outer membrane increases the ability of lysozyme to access its peptidoglycan target. A second possibility is that the loss of membrane structural support provided by LPS results in strains that are unable to withstand hydrolysis of peptidoglycan components by lysozyme. These data may suggest that the lpxa, lpxc and lpxd genes could serve as targets for the development of novel antimicrobials since their inhibition may lead to increased bacterial susceptibility to certain host antimicrobials, and therefore increased bacterial clearance by the innate immune response. This idea is supported by a recent study in which an LpxC inhibitor was able to increase bacterial clearance and reduce mortality in mouse model of A. baumannii infection in spite of the fact that the inhibitor did not demonstrate bactericidal activity (23). Taken together with previously reported data demonstrating the reduced activity of LL-37 and human lysozyme on strains with mutations in the PmrAB system (10), the results presented here indicate that the activity of the host cationic antimicrobials LL-37 and lysozyme on colistin resistant strains of A. baumannii is dependent upon the mechanism of colistin resistance. 7
8 Acknowledgements This work was funded by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III - co-financed by European s Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008/0000) and a grant from the European Community s 7 th Programme Framework (MagicBullet; Grant Agreement Number: ). MJM is supported by the Subprograma Miguel Servet from the Ministerio de Economía y Competitividad of Spain (CP11/00314). Transparency Declaration JP and MJM own stock in Vaxdyn, S.L., a biotechnology company developing vaccines for multidrug resistant bacteria, including A. baumannii. The other authors declare no potential conflicts of interest. Downloaded from on August 31, 2018 by guest 8
9 References 1. López-Rójas R, Jiménez-Mejías ME, Lepe JA, Pachón J Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis 204: Taccone FS, Rodríguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL, Jacobs F Successful treatment of septic shock due to panresistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 25: Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández- Cuenca F, Garnacho-Montero J, Cisneros JM, Ortiz C, Pachón J, Aznar J Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 30: Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53: Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrab two-component regulatory system. Antimicrob Agents Chemother 55: Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD Insertion sequence ISAba11 is involved in colistin resistance and loss of 9
10 lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 55: Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54: Vandamme D, Landuyt B, Luyten W, Schoofs L A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 280: Moffatt JH, Harper M, Mansell A, Crane B, Fitzsimons TC, Nation RL, Li J, Adler B, Boyce JD Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37. Infect Immun 81: Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, Pohl J, Lesho EP, Weiss DS Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. MBio 4:e Callewaert L, Van Herreweghe JM, Vanderkelen L, Leysen S, Voet A, Michiels CW Guards of the great wall: bacterial lysozyme inhibitors. Trends Microbiol 20: During K, Porsch P, Mahn A, Brinkmann O, Gieffers W The nonenzymatic microbicidal activity of lysozymes. FEBS Lett 449:
11 Ibrahim HR, Thomas U, Pellegrini A A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J Biol Chem 276: Fernández-Cuenca F, Pascual A, Ribera A, Vila J, Bou G, Cisneros JM, Rodríguez-Baño J, Pachón J, Martínez-Martínez L [Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)]. Enferm Infecc Microbiol Clin 22: Clinical Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; Twenty-third informational supplement. CLSI document M100-S23. Wayne, PA. Clinical Laboratory Standards Institute. 16. Fernández-Reyes M, Rodríguez-Falcon M, Chiva C, Pachón J, Andreu D, Rivas L The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 9: Schaub IG, Hauber FD A biochemical and serological study of a group of identical unidentifiable gram-negative bacilli from human sources. J Bacteriol 56: Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76: Sorensen O, Cowland JB, Askaa J, Borregaard N An ELISA for hcap-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 206:
12 Cole AM, Liao HI, Stuchlik O, Tilan J, Pohl J, Ganz T Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 169: Sochacki KA, Barns KJ, Bucki R, Weisshaar JC Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc Natl Acad Sci U S A 108:E Durr UH, Sudheendra US, Ramamoorthy A LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758: Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernández L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio 3. 12
13 261 Table 1. Colistin MIC values and endotoxin levels of strains used in this study. Colistin Strain Description MIC (mg/l) EU/10 6 cells a Reference Ab-84 Multidrug resistant clinical isolate ,78 ± 3,54 14 Ab-108 Ab-167 Ab-176 Ab-84R Ab-108R Ab-167R Ab-176R ATCC RC64 Multidrug resistant clinical isolate Multidrug resistant clinical isolate Multidrug resistant clinical isolate Strain Ab-84 containing a 40 nucleotide insertion at nucleotide 321 of lpxc generating a premature stop codon Strain Ab-108 with a T614A mutation in lpxa producing an I205N amino acid substitution Strain Ab-167 containing an ISAba1 insertion at nucleotide 321 of lpxc Strain Ab-176 with a G739T substitution at nucleotide 739 of the lpxd gene producing a premature stop codon Colistin-susceptible A. baumannii type strain. Derivative of ATCC containing R134C and A227V mutations in pmrb > 128 > 128 > 128 > ,53 ± 4,80 20,02 ±2,36 42,97 ±21,52 < 1 < 1 < 1 < 1 ND ND This study This study This study This study CS01 Colistin susceptible A. baumannii clinical isolate 0.25 ND CR17 Colistin-resistant derivative of 64 ND 1 CS01 containing a M12K mutations in pmra a Data represent the mean ± the standard error of the mean of three independent assays. EU; Endotoxin Units, ND; not determined 13
14 Figure Legend Figure 1. Activity of LL-37 and human lysozyme against A. baumannii strains. Graphs represent the percent survival of the strains after incubation with the indicated concentrations of LL-37 (A) and human lysozyme (B). Error bars represent the standard deviations of three independent cultures. * p < 0.05; Student s t test. Downloaded from on August 31, 2018 by guest 14
15
Title: Colistin resistance in a clinical Acinetobacter baumannii strain appearing after
AAC Accepts, published online ahead of print on 8 July 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00543-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Title: Colistin
More informationInhibition of LpxC increases antibiotic susceptibility in Acinetobacter. baumannii
AAC Accepted Manuscript Posted Online 6 June 0 Antimicrob. Agents Chemother. doi:10.118/aac.00407- Copyright 0, American Society for Microbiology. All Rights Reserved. 1 SHORT-FORM PAPER 3 4 Inhibition
More informationQuantitative real-time PCR for the detection of Acinetobacter. baumannii colonization in the hospital environment
JCM Accepts, published online ahead of print on 1 February 2012 J. Clin. Microbiol. doi:10.1128/jcm.06566-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 SHORT-FROM ARTICLE
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationIn Vivo Selection of Pan-Drug Resistant Acinetobacter baumannii during Antibiotic Treatment
Original Article http://dx.doi.org/10.3349/ymj.2015.56.4.928 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 56(4):928-934, 2015 In Vivo Selection of Pan-Drug Resistant Acinetobacter baumannii during Antibiotic
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPolymerase chain reaction#$
1393/2/2: 1393/6/24: 1393 "#!/31 / Polymerase chain reaction#$ "! 3 2 1 %&' " $'.' *+, ) '( & %"#$$! : % %5& 3 67 %54 ) 3 %"#$12 ) ' (Acinetobacter baumannii) PCR * ) $= %5)( "# #? Acinetobacter baumannii
More informationGrowth Retardation, Reduced Invasiveness and Impaired Colistin-Mediated Cell
AAC Accepts, published online ahead of print on 18 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01439-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Growth
More informationO. Oikonomou 1, S. Sarrou 1, C. C. Papagiannitsis 1,2, S. Georgiadou 3, K. Mantzarlis 4, E. Zakynthinos 4, G. N. Dalekos 3 and E.
Oikonomou et al. BMC Infectious Diseases (2015) 15:559 DOI 10.1186/s12879-015-1297-x RESEARCH ARTICLE Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece:
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationReceived 10 November 2006/Returned for modification 9 January 2007/Accepted 17 July 2007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2007, p. 3726 3730 Vol. 51, No. 10 0066-4804/07/$08.00 0 doi:10.1128/aac.01406-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparative
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationMultiple drug resistance pattern in Urinary Tract Infection patients in Aligarh
Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh Author(s): Asad U Khan and Mohd S Zaman Vol. 17, No. 3 (2006-09 - 2006-12) Biomedical Research 2006; 17 (3): 179-181 Asad
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationAntimicrobial susceptibility testing of Campylobacter jejuni and C. coli. CRL Training course in AST Copenhagen, Denmark 23-27th Feb.
Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli CRL Training course in AST Copenhagen, Denmark 23-27th Feb. 2009 Methodologies E-test by AB-biodisk A dilution test based on the
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationIn-vitro Activity of Telavancin in Combination with Colistin versus Gram-
AAC Accepts, published online ahead of print on 9 April 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05870-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 In-vitro
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationImpact of Spores on the Comparative Efficacies of Five Antibiotics. Pharmacodynamic Model
AAC Accepts, published online ahead of print on 12 December 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01109-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationCell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017
Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationActivity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationOriginal Article. Suthan Srisangkaew, M.D. Malai Vorachit, D.Sc.
Original Article Vol. 21 No.1 The optimum agent for ESBL screening and confirmatory tests:- Srisangkaew S & Vorachit M. 1 The Optimum Agent for Screening and Confirmatory Tests for Extended-Spectrum Beta-Lactamases
More informationIn vitro Comparison of Anti-Biofilm Effects against
Original Article http://dx.doi.org/10.3947/ic.2015.47.1.27 Infect Chemother 2015;47(1):27-32 ISSN 2093-2340 (Print) ISSN 2092-6448 (Online) Infection & Chemotherapy In vitro Comparison of Anti-Biofilm
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationInfluence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationEffect of pulmonary surfactant on antimicrobial activity in-vitro
AAC Accepts, published online ahead of print on 22 July 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00778-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Effect of pulmonary
More informationNitric Oxide is Bactericidal to the ESKAPE Pathogens: Time for a radical approach
Nitric Oxide is Bactericidal to the ESKAPE Pathogens: Time for a radical approach Kimberly A. Coggan, Ph.D. Infections caused by drug-resistant bacteria kill more Americans every year than colon and breast
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationAntibiotics & Resistance
What are antibiotics? Antibiotics & esistance Antibiotics are molecules that stop bacteria from growing or kill them Antibiotics, agents against life - either natural or synthetic chemicals - designed
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationOld drug, new findings: colistin resistance and dependence of Acinetobacter baumannii
REVIEW ARTICLE Precision and Future Medicine 2017;1(4):159-167 pissn: 2508-7940 eissn: 2508-7959 Old drug, new findings: colistin resistance and dependence of Acinetobacter baumannii Kwan Soo Ko, Yujin
More informationPrevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationInternational Journal of Pharma and Bio Sciences COLISTIN RESISTANCE IN ACINETOBACTER LWOFFII ABSTRACT
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 COLISTIN RESISTANCE IN ACINETOBACTER LWOFFII ABHISEK ROUTRAY *, ANU M.SAND RADHA MADHAVAN SRM Medical College
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationBIOLACTAM. Product Description. An innovative in vitro diagnostic for the rapid quantitative determination of ß-lactamase activity
BIOLACTAM www.biolactam.eu An innovative in vitro diagnostic for the rapid quantitative determination of ß-lactamase activity 1.5-3h 20 Copyright 2014 VL-Diagnostics GmbH. All rights reserved. Product
More informationInhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis
RESEARCH ARTICLE Inhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis Lin Lin, a,b Brandon Tan, a Paul Pantapalangkoor, a Tiffany
More informationThe First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran
1 2 The First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran Sedigheh Rafiei Tabatabaei, MD, MPH Associate Professor of Pediatric Infectious Diseases
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationThe Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University
The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3 Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University Tae-yoon Choi ABSTRACT BACKGROUND: The use of disinfectants
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationR-factor mediated trimethoprim resistance: result of two three-month clinical surveys
Journal of Clinical Pathology, 1978, 31, 850-854 R-factor mediated trimethoprim resistance: result of two three-month clinical surveys S. G. B. AMYES1, A. M. EMMERSON2, AND J. T. SMITH3 From the 'Department
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAntimicrobials & Resistance
Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationPresence of extended spectrum β-lactamase producing Escherichia coli in
1 2 Presence of extended spectrum β-lactamase producing Escherichia coli in wild geese 3 4 5 A. Garmyn* 1, F. Haesebrouck 1, T. Hellebuyck 1, A. Smet 1, F. Pasmans 1, P. Butaye 2, A. Martel 1 6 7 8 9 10
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationBoosting Bacterial Metabolism to Combat Antibiotic Resistance
Boosting Bacterial Metabolism to Combat Antibiotic Resistance The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation As Published
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationDecrease of vancomycin resistance in Enterococcus faecium from bloodstream infections in
AAC Accepted Manuscript Posted Online 30 March 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.00513-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 Decrease of vancomycin
More informationABSTRACT ORIGINAL RESEARCH. Gunnar Kahlmeter. Jenny Åhman. Erika Matuschek
Infect Dis Ther (2015) 4:417 423 DOI 10.1007/s40121-015-0095-5 ORIGINAL RESEARCH Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014
More informationClinical Center of Microbiology Research, Ilam University of Medical Sciences, Ilam, Iran b
Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2014; 9(2): 162-167 ORIGINAL PAPERS Detection of Highly Ciprofloxacin Resistance Acinetobacter Baumannii Isolated from Patients
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationIn vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Journal of Antimicrobial Chemotherapy Advance Access published February 8, 2007 Journal of Antimicrobial Chemotherapy doi:.93/jac/dkl52 In vitro pharmacodynamics of colistin against Acinetobacter baumannii
More informationPublic Assessment Report. Scientific discussion. Xiflodrop 5 mg/ml eye drops, solution. Moxifloxacin hydrochloride DK/H/2221/001/DC
Public Assessment Report Scientific discussion Xiflodrop 5 mg/ml eye drops, solution Moxifloxacin hydrochloride DK/H/2221/001/DC This module reflects the scientific discussion for the approval of Xiflodrop.
More informationRandall Singer, DVM, MPVM, PhD
ANTIBIOTIC RESISTANCE Randall Singer, DVM, MPVM, PhD Associate Professor of Epidemiology Department of Veterinary and Biomedical Sciences University of Minnesota Overview How does resistance develop? What
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationOriginal Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.
Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services
More informationAntimicrobial susceptibility testing of Campylobacter jejuni and C. coli
Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli CRL Campylobacter Workshop The 7th -8th of Oct. 2008 National Veterinary Institute Uppsala, Sweden Legislation The Commission has
More informationA review on multidrug - resistant Acinetobacter baumannii
ISSN: 2319-7706 Volume 3 Number 2 (2014) pp. 9-13 http://www.ijcmas.com Review Article A review on multidrug - resistant Acinetobacter baumannii Pavani Gandham* Department of Microbiology, Apollo Institute
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT COLICEN 4.000.000 UI/ml solution for use in drinking water/milk 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationThe Hospital Environment as a Source of Resistant Gram Negatives
Avondale College ResearchOnline@Avondale Nursing and Health Conference Papers Faculty of Nursing and Health 2013 The Hospital Environment as a Source of Resistant Gram Negatives Brett G. Mitchell Avondale
More informationMechanisms and Pathways of AMR in the environment
FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14
More informationMolecular identification of tigecycline- and colistinresistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013
Journal of Medical Microbiology (2015), 64, 993 997 DOI 10.1099/jmm.0.000127 Molecular identification of tigecycline- and colistinresistant carbapenemase-producing Acinetobacter baumannii from a Greek
More informationDetection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary Care Hospital in North India
Original Article Vol. 25 No. 3 Ampc β-lactamase Production in Gram-Negative Bacilli:-Chaudhary U, et al. 129 Detection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary
More informationAntimicrobial Resistance Initiative
Antimicrobial Resistance Initiative Antimicrobial Resistance Initiative Resistance to antimicrobial agents has become a threat to public health all over the world. Microorganisms become resistant to antimicrobial
More information